Product Description
Moxifloxacin is used to treat bacterial infections in many different parts of the body. It is also used to treat and prevent plague (including pneumonic and septicemic plague). Moxifloxacin belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. (Sourced from: https://www.mayoclinic.org/drugs-supplements/moxifloxacin-oral-route/side-effects/drg-20072313?p=1)
Mechanisms of Action: HERG Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, South Africa, Spain, Switzerland, Tanzania, Uganda, United Kingdom, United States
Active Clinical Trial Count: 13
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Capsule Opacification|Cataract|Conjunctivitis, Bacterial|Endophthalmitis|Fractures, Open|Influenza, Human|Otitis Externa|Pneumonia|Pneumonia, Bacterial
Phase 2: Tuberculosis, Pulmonary
Phase 1: Healthy Volunteers|Multiple Sclerosis|Scleroderma, General
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CN007-1005 | P1 |
Recruiting |
Healthy Volunteers |
2025-06-19 |
69% |
2025-04-02 |
|
| CTR20240536 | P1 |
Completed |
Pneumonia, Bacterial |
2024-09-29 |
2025-04-29 |
Primary Completion Date|Start Date|Study Completion Date |
|
| IPX203-102-23 | P1 |
Completed |
Healthy Volunteers |
2023-12-03 |
12% |
2024-11-27 |
|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
Scleroderma, General|Multiple Sclerosis |
None |
|||
| PARADIGM4TB | P2 |
Recruiting |
Tuberculosis, Pulmonary |
2027-02-24 |
50% |
2024-11-27 |
|
| 2018-000641-39 | P2 |
Active, not recruiting |
Otitis Externa |
2020-12-28 |
2025-07-02 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| CTR20130195 | P2 |
Recruiting |
Pneumonia |
2013-11-30 |
2025-04-29 |
Patient Enrollment |
|
| DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2027-12-31 |
2025-05-02 |
Treatments |
|
| REMAP-CAP | P3 |
Recruiting |
COVID-19|Pneumonia|Influenza, Human |
2026-02-01 |
2024-11-27 |
||
| PIND 134134 | P3 |
Not yet recruiting |
Endophthalmitis|Cataract|Capsule Opacification |
2025-10-01 |
6% |
2024-11-27 |
Primary Endpoints|Start Date|Treatments |
| 2017-002730-23 | P3 |
Active, not recruiting |
Conjunctivitis, Bacterial |
2017-05-26 |
2025-06-28 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| 2018-000615-25 | P3 |
Active, not recruiting |
Otitis Externa |
2015-12-29 |
2025-06-29 |
Primary Completion Date|Start Date|Study Completion Date |
|
| CTR20232386 | P3 |
Not yet recruiting |
Pneumonia, Bacterial |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/21/2025 |
News Article |
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies |
|
05/16/2025 |
News Article |
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference |
|
04/24/2025 |
News Article |
Price of Key DR-TB Medicine Drops 25% as TB Alliance's Multi-Manufacturer Strategy Expands Access |
|
04/10/2025 |
News Article |
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025 |